Related Experiment Video
Updated: Jun 21, 2026

Identification of Nucleolar Factors During HIV-1 Replication Through Rev Immunoprecipitation and Mass Spectrometry
Published on: June 26, 2019
Glucose-regulated protein 78 is an intracellular antiviral factor against hepatitis B virus
Yan Ma1, Jun Yu, Henry L Y Chan
1Stanley Ho Center for Emerging Infectious Diseases, School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong, China.
Insights
Glucose-regulated protein 78 (GRP78) acts as an endogenous anti-Hepatitis B virus (HBV) factor. Upregulating GRP78 may offer a novel therapeutic strategy for treating HBV infection.
Area of Science:
- Hepatology
- Virology
- Molecular Biology
Background:
- Hepatitis B virus (HBV) infection is a major cause of chronic liver disease, cirrhosis, and hepatocellular carcinoma.
- The precise mechanisms of HBV pathogenesis and host-virus interactions remain incompletely understood.
- Identifying host factors involved in HBV replication is crucial for developing new therapies.
Purpose of the Study:
- To investigate host protein expression changes in response to HBV replication.
- To elucidate the role of glucose-regulated protein 78 (GRP78) in HBV infection.
- To explore the potential of GRP78 as a therapeutic target for Hepatitis B.
Main Methods:
- Comparative proteomics using two-dimensional gel electrophoresis and mass spectrometry on an inducible HBV-producing cell line (HepAD38).
- Validation of differentially expressed proteins, including GRP78, using real-time RT-PCR, Western blotting, and immunohistochemistry in cell lines and human liver biopsies.
- Functional studies involving RNA interference (knockdown) and overexpression of GRP78 in HBV-producing cells.
Main Results:
- Twenty-three differentially expressed proteins were identified, with GRP78 significantly upregulated during HBV replication.
- Knockdown of GRP78 enhanced HBV replication and antigen production, while GRP78 overexpression suppressed HBV.
- GRP78 overexpression activated the interferon-beta1 (IFN-beta1)-mediated 2',5'-oligoadenylate synthetase-RNase L pathway.
- GRP78 was downregulated in chronic hepatitis B patients post-treatment, suggesting its role in viral clearance.
Conclusions:
- GRP78 functions as an endogenous anti-HBV factor in hepatocytes through the IFN-beta1 signaling pathway.
- The study identifies GRP78 as a key host-virus interaction protein in HBV infection.
- Induction of hepatic GRP78 presents a potential novel therapeutic strategy for managing HBV infection.
Abstract:
Hepatitis B virus (HBV) infection is a global public health problem that plays a crucial role in the pathogenesis of chronic hepatitis, cirrhosis, and hepatocellular carcinoma. However, the pathogenesis of HBV infection and the mechanisms of host-virus interactions are still elusive. In this study, two-dimensional gel electrophoresis and mass spectrometry-based comparative proteomics were applied to analyze the host response to HBV using an inducible HBV-producing cell line, HepAD38. Twenty-three proteins were identified as differentially expressed with glucose-regulated protein 78 (GRP78) as one of the most significantly up-regulated proteins induced by HBV replication. This induction was further confirmed in both HepAD38 and HepG2 cells transfected with HBV-producing plasmids by real time RT-PCR and Western blotting as well as in HBV-infected human liver biopsies by immunohistochemistry. Knockdown of GRP78 expression by RNA interference resulted in a significant increase of both intracellular and extracellular HBV virions in the transient HBV-producing HepG2 cells concomitant with enhanced levels of hepatitis B surface antigen and e antigen in the culture medium. Conversely overexpression of GRP78 in HepG2 cells led to HBV suppression concomitant with induction of the positive regulatory circuit of GRP78 and interferon-beta1 (IFN-beta1). In this connection, the IFN-beta1-mediated 2',5'-oligoadenylate synthetase and RNase L signaling pathway was noted to be activated in GRP78-overexpressing HepG2 cells. Moreover GRP78 was significantly down-regulated in the livers of chronic hepatitis B patients after effective anti-HBV treatment (p = 0.019) as compared with their counterpart pretreatment liver biopsies. In conclusion, the present study demonstrates for the first time that GRP78 functions as an endogenous anti-HBV factor via the IFN-beta1-2',5'-oligoadenylate synthetase-RNase L pathway in hepatocytes. Induction of hepatic GRP78 may provide a novel therapeutic approach in treating HBV infection.
Related Concept Videos
Hepatitis
Cell Specific Gene Expression
Inhibitors Of Virion Release
Inhibitors of Viral Protein Synthesis
Glucose Homeostasis: Regulation of Blood Glucose
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
Hormones Regulating Blood Glucose
In addition to accelerating glucose uptake and utilization, insulin has...

